Cancer remains a top priority for health systems around the world as incidence levels rise, fueled by growing and aging populations. While some incidence is preventable and early diagnosis and treatment can reduce or delay mortality significantly the reality is that countries struggle to bring together the right combination of measures including vaccines, diagnostics and therapeutics.
The economic consequences of cancer also make it a priority due to the impact of patient and caregiver productivity loss, and rising treatment costs. Recent increases in the numbers of new treatment options raise concerns about affordability for publicly and privately funded health systems alike.
In this report, we bring together the most comprehensive review of current trends in the oncology market, the state of innovation in therapeutics, measures of the value of treating cancer, and pricing trends. The report also assesses the opportunity for biosimilars to reshape the oncology drug market, especially in low and middle income countries, and the specific dynamics playing out in the U.S. where changes in site of care and patient sharing of costs associated with cancer treatment are having a significant impact on costs and behaviors.
Read full document: Innovation in cancer care and implications for health systems